Developing a holistic approach to cardio, metabolic and renal disease
With cardiovascular disease continuing to present a significant health concern, EPR’s Hannah Balfour reflects on recent development efforts and drug approvals in the space with comment from Dr Douglas Clark of Boehringer Ingelheim.